Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Global Forecast 2024-2030
The Acromegaly Treatment Market size was estimated at USD 2.48 billion in 2023 and expected to reach USD 2.72 billion in 2024, at a CAGR 9.92% to reach USD 4.81 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Acromegaly Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acromegaly Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Acromegaly Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Services (UK) Limited, Aetna Inc., Amolyt Pharma SAS, Amryt Pharma PLC, Bayer AG, Biodexa Pharmaceuticals PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Crinetics Pharmaceuticals, Inc., DexTech Medical AB, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Foresee Pharmaceuticals Co., Ltd., Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals, Inc., Ipsen Pharma, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Peptron Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, and Xeris Pharmaceuticals, Inc..
Market Segmentation & Coverage
This research report categorizes the Acromegaly Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
Disease Type
Ectopic Acromegaly
Bromocriptine Mesylate (Parlodel)
Hospital Pharmacies
Ambulatory Surgical Centers
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Acromegaly Treatment Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acromegaly Treatment Market?
- What are the technology trends and regulatory frameworks in the Acromegaly Treatment Market?
- What is the market share of the leading vendors in the Acromegaly Treatment Market?
- Which modes and strategic moves are suitable for entering the Acromegaly Treatment Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Acromegaly Treatment Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of genetic & hormonal diseases worldwide
- 5.1.1.2. Rising awareness regarding acromegaly diagnosis & treatment
- 5.1.1.3. Adoption of surgical procedures and radiation therapies for acromegaly treatment
- 5.1.2. Restraints
- 5.1.2.1. High cost of acromegaly treatment and incidences of drug recalls
- 5.1.3. Opportunities
- 5.1.3.1. Development of new acromegaly drug formulations and route of administration
- 5.1.3.2. Hormone therapy approvals for acromegaly treatments
- 5.1.4. Challenges
- 5.1.4.1. Side effects associated with drug treatments
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Acromegaly Treatment Market, by Disease Type
- 6.1. Introduction
- 6.2. Ectopic Acromegaly
- 6.3. Pseudo Acromegaly
- 7. Acromegaly Treatment Market, by Drug Class
- 7.1. Introduction
- 7.2. Bromocriptine Mesylate (Parlodel)
- 7.3. Dopamine Agonists
- 7.4. Growth Hormone Receptor Antagonist
- 7.5. Somatostatin Analogs (SSAs)
- 7.6. Somatuline Depot (Lanreotide)
- 7.7. Somavert (Pegvisomant)
- 8. Acromegaly Treatment Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Hospital Pharmacies
- 8.3. Online Pharmacies
- 8.4. Retail Pharmacies
- 9. Acromegaly Treatment Market, by End-User
- 9.1. Introduction
- 9.2. Ambulatory Surgical Centers
- 9.3. Homecare Settings
- 9.4. Hospitals & Clinics
- 10. Americas Acromegaly Treatment Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Acromegaly Treatment Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Acromegaly Treatment Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. AbbVie Inc.
- 14.1.2. Advanz Pharma Services (UK) Limited
- 14.1.3. Aetna Inc.
- 14.1.4. Amolyt Pharma SAS
- 14.1.5. Amryt Pharma PLC
- 14.1.6. Bayer AG
- 14.1.7. Biodexa Pharmaceuticals PLC
- 14.1.8. Boehringer Ingelheim International GmbH
- 14.1.9. Bristol-Myers Squibb Company
- 14.1.10. Crinetics Pharmaceuticals, Inc.
- 14.1.11. DexTech Medical AB
- 14.1.12. Dr. Reddy's Laboratories Ltd.
- 14.1.13. Eli Lilly and Company
- 14.1.14. Foresee Pharmaceuticals Co., Ltd.
- 14.1.15. Hikma Pharmaceuticals PLC
- 14.1.16. Ionis Pharmaceuticals, Inc.
- 14.1.17. Ipsen Pharma
- 14.1.18. Lupin Pharmaceuticals, Inc.
- 14.1.19. Merck & Co., Inc.
- 14.1.20. Mylan N.V.
- 14.1.21. Novartis AG
- 14.1.22. Peptron Inc.
- 14.1.23. Pfizer Inc.
- 14.1.24. Teva Pharmaceutical Industries Ltd.
- 14.1.25. Validus Pharmaceuticals LLC
- 14.1.26. Xeris Pharmaceuticals, Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. ACROMEGALY TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. ACROMEGALY TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. ACROMEGALY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ACROMEGALY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ACROMEGALY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ACROMEGALY TREATMENT MARKET DYNAMICS
- FIGURE 7. ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 8. ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 10. ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 12. ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 14. ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. ACROMEGALY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. ACROMEGALY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook